Reckitt Benckiser Group (OTCMKTS:RBGLY) Upgraded to Strong-Buy by Barclays

Reckitt Benckiser Group (OTCMKTS:RBGLY) was upgraded by analysts at Barclays to a “strong-buy” rating in a note issued to investors on Friday, Zacks.com reports.

Several other equities research analysts have also weighed in on the company. UBS Group raised Reckitt Benckiser Group to a “strong-buy” rating in a research report on Wednesday, September 18th. Citigroup raised Reckitt Benckiser Group to a “strong-buy” rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. cut Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 29th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Reckitt Benckiser Group Price Performance

RBGLY stock opened at $11.93 on Friday. Reckitt Benckiser Group has a 12-month low of $10.24 and a 12-month high of $15.03. The stock’s 50 day simple moving average is $11.56 and its 200 day simple moving average is $11.30.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.